ArteraAI Included in the 2024 NCCN Guidelines® for Prostate Cancer
The multimodal artificial intelligence (MMAI) test is the first AI-enabled tool recognized in national guidelines for both pr [...]
ArteraAI Secures $20 Million in Funding to Further Personalize Cancer Therapy With Multimodal AI
The funding will support the international expansion and commercial growth of the company and its first-of-its-kind test SAN [...]
ArteraAI Receives Medicare Payment Rate for the ArteraAI Prostate Cancer Test
This is the first-of-its-kind AI-enabled test to provide predictive and prognostic results SAN FRANCISCO--(BUSINESS WIRE)--Ar [...]
ArteraAI Announces Research Agreement with CorePlus
The collaboration aims to further validate the ArteraAI Prostate Test in the Hispanic population SAN FRANCISCO--(BUSINESS WIR [...]
ArteraAI and GenesisCare Partner to Launch the First Australian-Based Clinical Trial
SAN FRANCISCO & SYDNEY--(BUSINESS WIRE)--ArteraAI, the developer of multimodal artificial intelligence (MMAI) based predi [...]
ArteraAI and GenesisCare Partner to Provide Precision Cancer Therapy to Patients with Localized Prostate Cancer In Australia
Patients treated at GenesisCare clinics in Australia can work with clinicians to access AI-based decision making tools as par [...]
ArteraAI Validates its Prognostic Model in Advanced Prostate Cancer
The model was successfully validated in Phase 3 STAMPEDE trials with stronger prognostic associations than individual clinica [...]
ArteraAI Announces First-Ever AI-Derived Biomarker for Predicting Androgen Deprivation Therapy (ADT) Benefit in Prostate Cancer
Data published in the NEJM Evidence shows promise for personalized use of short-term ADT in men with predominantly intermedia [...]
ArteraAI Presents New Data Validating AI-Derived Predictive Biomarker at 2023 ASCO Annual Meeting
The biomarker is the first to predict long-term ADT usage in men with high-risk localized prostate cancer SAN FRANCISCO--(BUS [...]